OncLive TV

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses risk factors for androgen deprivation therapy (ADT)-associated cardiac complications in prostate cancer.

Robert J. Cerfolio, MD, director of the Lung Cancer Center, chief of clinical thoracic surgery, NYU Langone’s Perlmutter Cancer Center, discusses the role of surgery in lung cancer.

Brandon G. Smaglo, MD, FACP, assistant professor of internal medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the FDA approval of TAS-102 (trifluridine/tipiracil; Lonsurf) in gastric/gastroesophageal junction (GEJ) adenocarcinoma.

Janakiraman Subramanian, MD, a medical oncologist and director of thoracic oncology and director of the Center for Precision Medicine at Saint Luke’s Cancer Institute, discusses tumor biology in lung cancer.

Vincent Chung, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, director of the Phase I Program, City of Hope, discusses the COMPASS trial in pancreatic cancer.

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment strategies for patients with oligometastatic prostate cancer.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses findings from the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses recognizing tumor sidedness in the treatment of patients with metastatic colorectal cancer.

Chip Landen, MD, associate professor, Division of Gynecologic Oncology, University of Virginia Health System, discusses the molecular subtypes of ovarian cancer.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses remaining questions regarding the use of immunotherapy in head and neck cancer that still need to be addressed.

Hussein A. Tawbi, MD, PhD, associate professor, The University of Texas MD Anderson Cancer Center, discusses unmet needs in melanoma.

Theresa Shao, MD, assistant professor of hematology-oncology, Icahn School of Medicine, Tisch Cancer Institute, Mount Sinai Health System, discusses the prognosis of patients with HER2-positive breast cancer.

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the toxicity profile of ruxolitinib in the treatment of patients with myeloproliferative neoplasms.

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses the current state of treatment for patients with non–small cell lung cancer.

Komal Jhaveri, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the potential for immunotherapy in the treatment of patients with triple-negative breast cancer (TNBC) based on results from the IMpassion130 trial.

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate professor of surgical oncology, City of Hope, discusses the benefit of cytoreductive surgery in the treatment of patients with metastatic colorectal cancer (mCRC).

Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses the treatment of patients with metastatic uterine leiomyosarcoma.

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Cancer Institute, HCA Midwest Health, discusses the patient populations that remain an unmet need in chronic lymphocytic leukemia (CLL).

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses strategies for managing central nervous system metastases in patients with oncogene-driven non–small cell lung cancer.

Ramez N. Eskander, MD, assistant clinical professor, Department of Reproductive Medicine, University of California, San Diego Moores Cancer Center, discusses the need for more effective biomarkers in the treatment of patients with ovarian cancer.

Sumit K. Subudhi, MD, PhD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rationale for the CheckMate-650 study in the treatment of patients with metastatic castration-resistant prostate cancer.

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses sustained responses with tisagenlecleucel in the treatment of patients with diffuse large B-cell lymphoma.

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses the role of melflufen in the treatment of patients with myeloma.

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses unmet needs in the treatment of patients with advanced urothelial cancer.

Douglas A. Nelson, MD, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel combination therapies in colorectal cancer (CRC).

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses induction therapy in patients with mantle cell lymphoma (MCL).

Elaine Shum, MD, medical oncologist, NYU Langone’s Perlmutter Cancer Center, discusses mechanisms of resistance in patients with oncogene-driven non–small cell lung cancer (NSCLC).

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone's Perlmutter Cancer Center, a 2016 Giant of Cancer Care in Melanoma, discusses the FDA approval of pembrolizumab for stage III melanoma.

Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses the racial genomics of prostate cancer.

J. Russell Davis, MD, clinical professor, University of Missouri–Kansas City School of Medicine, thoracic surgeon, Saint Luke's Hospital, compares the use of robotic surgery with open surgery in patients with lung cancer.